Studying Fentanyl in Patients With Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2 enrolled

Overview

RATIONALE: Studying blood samples from cancer patients undergoing pain treatment in the laboratory may help doctors learn more about how pain drugs work in the body. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at fentanyl in patients with cancer.

OBJECTIVES: * To describe the pharmacokinetics of prolonged intravenous infusions of fentanyl citrate in adult patients with cancer. OUTLINE: Patients undergo blood sample collection before and after discontinuation of fentanyl citrate therapy (10 days total). Pharmacokinetic analysis is performed on the samples.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Brain and Central Nervous System Tumors Chronic Myeloproliferative Disorders Leukemia Lymphoma Lymphoproliferative Disorder Multiple Myeloma and Plasma Cell Neoplasm

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Diagnosis of cancer * Inpatient at the Johns Hopkins Hospital Cancer Center undergoing pain treatment with continuous infusion fentanyl citrate for ≥ 5 days PATIENT CHARACTERISTICS: * Willing to change to an alternative opioid PRIOR CONCURRENT THERAPY: * See Disease Characteristics * At least 72 hours since transdermal fentanyl citrate administration * At least 12 hours since transmucosal fentanyl citrate administration * No known requirement for continued opioid therapy with any fentanyl citrate products after discontinuation of fentanyl citrate therapy

Outcomes

Primary Outcomes

Pharmacokinetics of fentanyl citrate

Time frame: two baseline samples, serial samples obtained at 0,4,8,24,48,72,96,168,240 hrs after discontinuing fentanyl